Madison, Wisconsin
Phase 3 cancer trials in Madison, WI
46 Phase 3 cancer studies are recruiting participants at sites in Madison as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Madison at a glance
- 46 studies are recruiting at a site in Madison.
- By phase: Phase 2/3 (3), Phase 3 (43).
- By sponsor: industry (22), university, hospital or other (20), government (4).
- By research area: Lymphoma (13), Breast Cancer (11), Lung Cancer (9), Prostate Cancer (8), Melanoma (3), Pancreatic Cancer (2).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Madison
Basic details from each study's public record (the 30 most recently updated of 46). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SSM Health Dean Medical Group ( Site 0087)
- Registry record
- NCT06393374 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Wisconsin-Madison ( Site 0024)
- Registry record
- NCT06966700 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT06058377 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- University of Wisconsin Carbone Cancer Center- University Hospital
- Registry record
- NCT06982521 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT05879926 · updated
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039)
- Registry record
- NCT07060807 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Madison, WI on ClinicalTrials.gov.
Lung cancer studies recruiting in Madison
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital · William S Middleton VA Medical Center
- Registry record
- NCT04267848 · updated
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)
- Registry record
- NCT06345729 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical
- Registry record
- NCT06119581 · updated
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- University Hospital and UW Health Clinics
- Registry record
- NCT06890598 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Madison, WI on ClinicalTrials.gov.
Prostate cancer studies recruiting in Madison
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital · William S Middleton VA Medical Center
- Registry record
- NCT04423211 · updated
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- William S Middleton VA Medical Center
- Registry record
- NCT06931340 · updated
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT07200830 · updated
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University Hospital and UW Health Clinics ( Site 0065)
- Registry record
- NCT06925737 · updated
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- NRG Oncology
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT05946213 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Madison, WI on ClinicalTrials.gov.
Melanoma studies recruiting in Madison
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- University of Wisconsin Carbone Cancer Center
- Registry record
- NCT06246916 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- University of Wisconsin
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Madison, WI on ClinicalTrials.gov.
Lymphoma studies recruiting in Madison
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Nuvation Bio Inc.
- Study site
- University of Wisconsin Health
- Registry record
- NCT05303519 · updated
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048) · University Hospital and UW Health Clinics ( Site 0006)
- Registry record
- NCT06136559 · updated
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT06724237 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SSM Health Dean Medical Group ( Site 0140)
- Registry record
- NCT06717347 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT05675410 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT03150693 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT05976763 · updated
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
- Registry record
- NCT07215910 · updated
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Phase 3
- Ages 65 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- William S Middleton VA Medical Center
- Registry record
- NCT07321652 · updated
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- University of Wisconsin
- Registry record
- NCT06742996 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Madison, WI on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Madison
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Investigative Site US044
- Registry record
- NCT07522073 · updated
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study site
- University of Wisconsin Carbone Cancer Center
- Registry record
- NCT07562152 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Madison, WI on ClinicalTrials.gov.
Ask about studies near Madison
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Wisconsin
All Wisconsin locations
93 studies recruiting across 61 cities.
Milwaukee
49 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections